GeneXpert MTB/RIF is a cartridge-based nucleic acid amplification test (NAAT) that allows for rapid, simultaneous detection of Mycobacterium tuberculosis (MTB) DNA and rifampicin (RIF) resistance. It has revolutionized tuberculosis (TB) diagnostics by providing results within approximately 90 minutes, dramatically reducing the time to diagnosis compared to conventional culture methods.
Background
Tuberculosis remains one of the leading infectious causes of morbidity and mortality worldwide. Traditional diagnostic methods include sputum smear microscopy, chest radiography, culture, and the Mantoux tuberculin skin test. While sputum smear microscopy is inexpensive and widely used, it has limited sensitivity—especially in patients with low bacterial load such as children and those coinfected with HIV.
Culture remains the gold standard for TB diagnosis and drug susceptibility testing but requires 2–6 weeks for MTB growth and several additional weeks for drug sensitivity testing. This delay contributes to ongoing transmission and hampers timely initiation of effective therapy, especially in cases of multi-drug resistant TB (MDR-TB).
Development and Endorsement
The GeneXpert MTB/RIF test was co-developed by Prof. David Alland’s lab at UMDNJ, Cepheid Inc., and the Foundation for Innovative New Diagnostics, with NIH funding support. In 2010, the World Health Organization (WHO) endorsed its use in TB-endemic regions after extensive evaluation in diverse patient populations, including those with TB/HIV coinfection.
The U.S. Centers for Disease Control and Prevention (CDC) has recognized GeneXpert as a “game changer” in TB control, given its ability to detect MTB and rifampicin resistance within 2 hours—versus weeks required by culture and phenotypic drug susceptibility testing.
Mechanism of Action
- Sample Processing: GeneXpert MTB/RIF uses unprocessed sputum specimens.
- Detection: It isolates and concentrates MTB bacilli via sonication.
- Amplification: DNA is extracted and amplified through real-time polymerase chain reaction (PCR).
- Resistance Testing: Molecular probes target mutations in the rpoB gene, which encodes the RNA polymerase beta subunit, to identify rifampicin resistance mutations.
- Output: Results appear as qualitative detection of MTB and rifampicin resistance in under 2 hours.
Clinical Performance
- Sensitivity & Specificity: GeneXpert exhibits excellent sensitivity (around 90%) and specificity (near 98%) for pulmonary TB detection, outperforming sputum smear microscopy, especially in smear-negative and HIV-positive patients.
- Limit of Detection: Approximately 131 colony-forming units (CFU)/mL, much lower than the ~10,000 CFU/mL threshold of smear microscopy.
- Resistance Detection: Accurately detects rifampicin resistance, a reliable proxy marker for MDR-TB (which requires complex treatment regimens).
Clinical Applications
- Rapid diagnosis of active pulmonary TB, particularly in HIV-coinfected and smear-negative patients.
- Early detection of rifampicin resistance, enabling timely initiation of MDR-TB treatment.
- Useful for extrapulmonary samples, although sensitivity varies by specimen type.
Advantages
- Fast turnaround (90 minutes).
- Minimal biosafety risk since sputum is processed inside closed cartridges.
- Simple operation requiring limited technical training.
- Can be deployed at point-of-care in resource-limited settings.
Limitations
- Cannot detect resistance to other anti-TB drugs besides rifampicin.
- False-negative results can occur in paucibacillary disease or if mutations lie outside the rpoB target region.
- Cost and infrastructure needs may limit widespread use in low-resource settings.
